XENEXenon Pharmaceuticals Inc.vs its industry peers
A metric-by-metric comparison of Xenon Pharmaceuticals Inc. against iShares Biotechnology ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XENEEsta | $3.8B#14 | — | 3.0x#2 | 500.3x#12 | — | -47.6%#14 | -4974.3%#14 | -27.8%#11 | -32.5%#11 | — | — | — |
| VRTX | $135.6B#4 | 34.4x#4 | 6.5x#5 | 11.3x#7 | 8.9%#8 | 838.1%#3 | 34.8%#2 | 18.9%#5 | 17.4%#6 | — | 25.5%#9 | — |
| AMGN | $250.6B#2 | 28.8x#3 | 21.4x#10 | 6.8x#4 | 10.0%#7 | 88.5%#7 | 24.7%#7 | 66.0%#1 | 15.1%#7 | — | 59.7%#6 | 2.0%#1 |
| GILD | $210.5B#3 | — | 16.1x#9 | 7.1x#5 | 2.4%#9 | 1672.9%#2 | 34.0%#3 | 65.3%#2 | 25.7%#3 | — | 41.7%#8 | 1.9%#2 |
| REGN | — | 21.5x#2 | — | — | 1.0%#11 | 2.1%#10 | 24.9%#6 | 13.4%#6 | 9.2%#9 | — | 51.6%#7 | — |
| ARGX | $54.8B#7 | — | — | 1540.8x#13 | 254.4%#1 | 55.1%#8 | 2965.7%#1 | — | — | — | 7.1%#12 | — |
| ALNY | $21.3B#13 | 8.3x#1 | 5.9x#4 | 5.7x#3 | 65.2%#3 | 212.8%#4 | 13.5%#9 | 8.7%#8 | 19.3%#5 | — | -63.3%#14 | — |
| NTRA | $56.3B#6 | — | 30.9x#11 | 24.4x#8 | 35.9%#5 | -9.3%#11 | -13.4%#11 | -11.4%#10 | -18.0%#10 | — | 97.1%#4 | — |
| RVMD | $41.9B#8 | — | 16.1x#8 | — | — | -88.5%#15 | — | -43.4%#13 | — | — | 229.1%#2 | — |
| BIIB | $37.1B#9 | 108.5x#7 | 2.5x#1 | 3.7x#1 | 2.2%#10 | -20.8%#12 | 28.7%#5 | 8.7%#7 | 12.3%#8 | 3#3 | 65.4%#5 | — |
| ILMN | $36.1B#10 | 41.1x#5 | 11.5x#6 | 8.3x#6 | -0.7%#12 | 169.5%#5 | 18.6%#8 | 27.0%#3 | 19.9%#4 | 8#1 | 99.0%#3 | — |
| MRNA | $92.5B#5 | — | 13.7x#7 | 47.6x#10 | -39.9%#13 | 20.8%#9 | -158.1%#12 | -41.7%#12 | -54.6%#12 | — | 830.5%#1 | — |
| INSM | $23.1B#12 | — | 31.8x#12 | 38.1x#9 | 66.7%#2 | -39.7%#13 | -205.6%#13 | -175.8%#14 | -141.2%#13 | 3#3 | -43.4%#13 | — |
| ONC | $526.8B#1 | 828.9x#8 | 101.8x#13 | 98.6x#11 | 40.2%#4 | 144.5%#6 | 8.4%#10 | 5.5%#9 | 29.9%#2 | 6#2 | 14.3%#11 | — |
| INCY | $24.1B#11 | 60.4x#6 | 4.3x#3 | 4.7x#2 | 21.2%#6 | 3846.9%#1 | 29.5%#4 | 22.8%#4 | 45.1%#1 | — | 16.5%#10 | — |
Peer set: top holdings of IBB (iShares Biotechnology ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice